Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib)
Puma Biotechnology, Inc., a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to…
Read More...
Read More...
